US FDA approves Novartis’ radioligand therapy for prostate cancer
The US agency has also approved complementary diagnostic imaging agent Locametz, to identify patients eligible for treatment using…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Mar 22
The US agency has also approved complementary diagnostic imaging agent Locametz, to identify patients eligible for treatment using…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Mar 22
Exposure to nitrosamines above Acceptable Daily Intake (ADI) levels for prolonged durations is believed to increase the risk…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Mar 22
In the lawsuit, Bristol Myers claimed that it has invented the methods for enhancing immune responses and has…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Mar 22
Swiss drugmaker Novartis, US-based Abbott Laboratories, AbbVie, Johnson & Johnson (J&J), Pfizer and Germany would withdraw from Russia
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Mar 22
Nitroglycerin sublingual tablet is used to relieve episodes of chest pain, called angina, in people with coronary artery…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Mar 22
The new site will use new technologies to enhance the efficiency and capability to produce a wide range…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Mar 22
Discovered at Zydus Research Centre, Oxemia is a differentiated HIF-PH Inhibitor, the first alternative to injectable erythropoietin-stimulating agents…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Mar 22
The new Enterprise Solutions Hub will support the US, Canada and Latin America, offering services similar to its…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
02 Mar 22
The acquisition will expand AbbVie's neuroscience portfolio with Syndesi’s synaptic vesicle protein 2A (SV2A) modulators, including its lead…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Feb 22
Through the acquisition, BBL will obtain rights to Viatris’ biosimilars business assets, which is estimated to generate $1bn…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates